The quality of a Th1 response can be a prospective correlate of vaccine-mediated protection against certain intracellular pathogens. Using two distinct vaccine platforms, we evaluate the influence of interleukin (IL) 10 production on the magnitude, quality, and protective capacity of CD4 + T cell responses in the mouse model of Leishmania major infection. Multiparameter flow cytometry was used to delineate the CD4 + T cell production of interferon ( 
CD4 + T cell responses after vaccination or in fection show substantial heterogeneity in terms of their phenotype and functional capacity. In ducing protective responses without the appro priate means to assess such heterogeneity has limited the ability to define correlates of protec tion after vaccination. Thus, understanding the type of CD4 + T cell response required to medi ate protection is critical for rational design of vaccines against infections requiring Th1 im munity. Historically, T cell responses have been characterized by magnitude (frequency), prolif erative capacity, or the mean TCR avidity. Re cently, multicolor flow cytometry has broadened the spectrum of parameters that can be measured simultaneously at the singlecell level to include phenotypic markers and/or specific combina tions of functional responses (e.g., cytokines). This more extensive characterization, termed quality, is defined by the pattern of cytokine production at the singlecell level (Seder et al., 2008) . The quality can be related to the spectrum of Th1 differentiation from IFN-negative, IL2-producing, and/or TNFproducing cen tral memory cells to multifunctional IFN + IL2 + TNF + or IFN + IL2  TNF + effector memory cells to terminally differentiated IFN singlepositive cells (Seder et al., 2008; Wu et al., 2002) . Furthermore, when quantified on a per cell basis, Th1 cells secreting all three cytokines (IFN + IL2 + TNF + ) produce considerably more IFN than double or singleproducing IFN cells (Darrah et al., 2007) . In addition, the ability of multifunctional Th1 cells to also secrete TNF could profoundly impact the efficiency and extent of Th1 differentiation by regulating production of IL12 by DCs. In this regard, we previously showed three immunizations with MML protein and the tolllike receptor (TLR) 9 ligand CpG (MML + CpG) are required to elicit a high frequency of multifunctional Th1 cells and protective immunity against L. major (Darrah et al., 2007) . As CpG is a potent inducer of IL10 and IL12 from DCs (Chu et al., 1997; Roman et al., 1997; Boonstra et al., 2006; Samarasinghe et al., 2006) , we hypothesized that this innate crossregulation after immu nization might influence the number of immunizations re quired to achieve protection and the type of Th1 response induced. Thus, the other major focus of the study was to examine the role IL10 and IL12 production from innate immune cells on Th1 immunity and protection after MML + CpG immunization.
In this study, we investigate how IL10 production by CD4 + T cells or APCs might influence the magnitude, qual ity, and protective capacity of Th1 responses elicited by MMLADV or MML + CpG immunization. Thus, a novel multiparameter flow cytometry panel was developed to de fine the quality of the MMLspecific response after vaccina tion, measured by the production of IL10, IFN, IL2, and TNF. In addition, IL10 / mice and WT mice treated with anti-IL10 receptor (IL10R) were used to define the role of innate and adaptive IL10 on vaccineinduced immunity and Th1mediated protection. Overall, this study delineates the mechanisms of how two distinct vaccine formulations generate protective immunity and elucidates the role that IL10 has on this process.
RESULTS

Characterization of distinct cytokine-producing CD4 + T cell populations using multiparameter flow cytometry
Immunization with highdose (10 10 viral particles [vp] ) and lowdose (10 7 vp) MMLADV results in a similar magnitude of IFN-producing CD4 + T cells but only lowdose MMLADV confers durable protection (Darrah et al., 2007) . One explanation for such findings is that lowdose MML ADV elicits a Th1 response of better quality than highdose MMLADV. However, it was recently shown that IL10 from CD4 + T cells contributes to susceptibility to L. major infection even in the presence of a strong Th1 response (Anderson et al., 2005 (Anderson et al., , 2007 . Thus, we developed a multipa rameter flow cytometry panel to investigate a role for CD4 + T cell-derived IL10 in vaccinemediated protection of mice after MMLADV. Fig. 1 outlines the gating strategy, cytokine analysis, and data presentation used in this study. Shown is the gating of CD4 + T cells (Fig. 1 A) used to quan tify the total frequency of IFN-, IL2-, TNF, or IL10-producing CD4 + T cells (Fig. 1 B) , as well as the Boolean analysis ( Fig. 1 C) and graphical representation (Fig. 1, D and E) of the 15 individual cytokine combinations of IFN, IL2, TNF, or IL10 produced by individual CD4 + T cells. The proportion (of the total response) of each cytokine alone or in any combination produced at the singlecell level and IL2 provides additional effector function and enhanced proliferative capacity, respectively, making these cells opti mized for durable effector function. The quality of a vaccine elicited response was first shown to be predictive of disease protection against Leishmania major in as much as a CD4 + T cell quality comprising a high frequency of multifunctional IFN + IL2 + TNF + Th1 cells correlated with protection (Darrah et al., 2007) . Moreover, this Th1based metric has since been cor related with a favorable outcome to a variety of other infec tions including tuberculosis (Forbes et al., 2008; Lindenstrøm et al., 2009) , malaria (Roestenberg et al., 2009) , and vaccinia (Trumpfheller et al., 2008) .
As the quality of a Th1 response may predict outcome against infection, understanding the mechanisms that influence the generation of multifunctional Th1 cells can be used to im prove vaccine design. Using various vaccine formulations or by altering the dose of a specific vaccine, we were able to elicit qualitatively distinct Th1 responses that confer varying levels of protection. Indeed, vaccination with a single low dose of MMLadenovirus (ADV) elicited a Th1 response comprising a high frequency of multifunctional cells and protection against L. major challenge, whereas a single high dose of MMLADV elicited fewer multifunctional cells, a high proportion of IFN singlepositive cells, and no protection (Darrah et al., 2007) . Although the lack of protection after highdose MMLADV immunization was consistent with a poor quality Th1 response, it remained possible that inhibitory cytokines, which have a well established role in limiting protection against L. major (Sacks and Anderson, 2004) , were influencing outcome. In this regard, IL10 produced by CD4 + T cells promotes suscep tibility and prevents healing in mice and humans infected with L. major (Sacks and Anderson, 2004) . In the context of a self healing L. major infection, IL10 from natural regulatory T (T reg) cells prevents the eradication of parasites, allowing a persistence of lowlevel antigen that sustains T cell memory (Belkaid et al., 2001 (Belkaid et al., , 2002 . Additionally, immune suppression during chronic L. major infection is mediated by IL10 production from IFN-producing Th1 cells (Anderson et al., 2007) . Thus, in the set ting of L. major infection in vivo, CD4 + T cell-derived IL10 prevents clearance of parasites. Alternatively, IL10 produced by Th1 cells can have an important regulatory effect by limit ing excess inflammation during Toxoplasma gondii or Flu infec tion (Jankovic et al., 2002; Sun et al., 2009) . Although these studies show that CD4 + T cell-derived IL10 can have distinct regulatory effects on an ongoing infection in vivo, it has not been shown whether CD4 + IFN + IL10 + Th1 cells can be elicited by vaccination with clinically based vectors or how they would influence the quality of the Th1 response or pro tection. Thus, a major focus of this study was to investigate a role for CD4 + T cell-derived (adaptive) IL10 after immuniza tion with highdose MMLADV vaccination and to determine its effect on Th1 quality and protection.
IL10 can also limit Th1 responses indirectly by decreas ing APC function or APC production of the canonical polar izing cytokine IL12 (Moore et al., 2001; Trinchieri, 2001) . Indeed, APCderived (innate) IL10 induced by vaccination T reg cells because all IL10 + cells were confined to the CD4 + CD25 -Foxp3  population (Fig. S1) . In assessing the quality of the response 10 and 28 d after vaccination, highdose MMLADV elicited CD4 + T cells that produced antigen specific IL10 alone or in combination with IFN or IFN and TNF (Fig. 2 B) . It is of note that there were low to unde tectable populations of CD4 + T cells that produced both IL10 and IL2 (Fig. 2 B) . With respect to IL10  populations, highdose MMLADV elicited a lesser frequency of IFN + IL2 + TNF + multifunctional Th1 cells compared with lowdose MMLADV (Fig. 2 B) , which is consistent with our previous findings (Darrah et al., 2007) . Thus, in comparing the overall quality of the Th1 response, highdose MMLADV elicits a heterogeneous CD4 + T cell cytokine response comprising a greater proportion of IL10-producing cells (Fig. 2 C, blue arc) and a lesser proportion of IFN + IL2 + TNF + reflects the quality of the response and is illustrated using pie charts (Fig. 1 E) .
High-dose MML-ADV immunization elicits a poor quality Th1 response and a high frequency of IL-10-producing CD4 + T cells Consistent with our previous studies, the total frequency of IFN-producing CD4 + splenocytes after i.m. vaccination of mice with highdose MMLADV (10 10 vp) was greater than with lowdose MMLADV (10 7 vp) at the peak of the im mune response (10 d after vaccination; Fig. 2 A, left) but equiv alent by the time of challenge (28 d after vaccination; Fig. 2 A  [right] ). Strikingly, a large frequency of IL10-producing CD4 + T cells was detectable 10 and 28 d after vaccination with high but not lowdose MMLADV (Fig. 2 A) . The IL10 produced was antigen specific and not derived from natural IL-10 signaling does not influence the generation of Th1 or IL-10-producing CD4 + T cells after immunization with high-dose MML-ADV The next series of experiments focused on how IL10 was elicited from CD4 + T cells after highdose MMLADV im munization and its effect, if any, on the quality of the immune response and protection. It is of note that IL10 itself has been shown to give rise to antigenspecific IL10 production from immunosuppressive CD4 + Tr1 cells (Groux et al., 1997) . Thus, mice were treated with IL10R at the time of priming to determine whether inhibition of IL10 signaling would influence the magnitude and quality of Th1 cells or IL10-producing CD4 + T cells. Treatment with IL10R at the time of i.m. (Fig. 3) or s.c. (Fig. S3 ) immunization with high dose MMLADV did not significantly alter the total frequency ( Fig. 3 A and Fig. S3 A) or the MFI ( multifunctional Th1 cells ( Fig. 2 C, red pie slice) compared with lowdose MMLADV. Additionally, in separate experi ments, similar results were observed using the s.c. route of im munization (Fig. S2 ). The production of IL10 by CD4 + T cells might counter act APCactivating signals to weaken pathogenkilling mecha nisms, accounting for the limited capacity of highdose MMLADV to protect. Alternatively, IL10 might cause an intrinsic defect in Th1 function such as reduced potency of IFN-producing effector populations that simultaneously se crete IL10. In this regard, the IFN median fluorescent in tensity (MFI) of CD4 + IFN + IL10 + T cells was not decreased compared with that of CD4 + IFN + IL10  cells (Fig. 2 D) , which is consistent with recently published data describing CD4 + IFN + IL10 + T cell populations during infection with T. gondii (Jankovic et al., 2007) . with lowdose MMLADV vaccination. Finally, in two sepa rate experiments the Th1 response elicited after i.m. or s.c. immunization with highdose MMLADV in the complete absence of IL10 did not confer protection compared with lowdose MMLADV, as determined by lesion progression (Fig. 4 D) or parasite burdens (Fig. 4 E) . It is of note that lesion progression after challenge of IL10 / mice was similar to what we have previously reported in WT C57BL/6 mice (Darrah et al., 2007) ; however, IL10 / mice displayed lower parasite burdens than WT mice irrespective of vaccination (unpublished data), which is consistent with previous results (Belkaid et al., 2001) . Collectively, these data show no signifi cant effect of IL10 by T cells or on T cells after highdose MMLADV immunization. Hence, the quality of the Th1 re sponse is a critical determinant of protection after highdose MMLADV vaccination, independent of IL10 production.
MML + CpG, but not MML-ADV, immunization elicits IL-10 and IL-12 production from innate immune cells
The prior data show that CD4 + T cell-derived IL10 after highdose MMLADV immunization did not influence pro tection. Moreover, inhibiting IL10 at the time of MMLADV immunization had no effect on Th1 immunity. Although these data suggest that IL10 is not involved in MMLADV-induced
Immunization with high-dose MML-ADV is not protective, even in the absence of IL-10
Because IL10 from IFN-producing CD4 + T cells has been shown to suppress parasite killing during chronic L. major in fection (Anderson et al., 2007) , we next determined whether the limited protection after highdose MMLADV immuniza tion was a result of vaccineinduced IL10 production by CD4 + T cells, poor Th1 quality, or both. Thus, we vaccinated WT or IL10 / mice with high or lowdose MMLADV. In data from three combined experiments, the total frequency of IFN-, IL2-, or TNFproducing CD4 + T cells from the spleen 21 d after i.m. (Fig. 4 A) or s.c. (Fig. S4 A) immuniza tion with highdose MMLADV was not significantly en hanced in IL10 / mice compared with WT mice, which is consistent with the data in the previous section using IL10R treatment. Moreover, the quality of the Th1 response gen erated in WT and IL10 / mice was identical when com paring the same dose and route of MMLADV vaccination ( immunity, we directly assessed production of IL10 by innate immune cells in vitro and in vivo after stimulation with MMLADV. To extend the innate profile, IL12 production was also examined. As shown in Fig. 5 , there was no detect able IL10 or IL12 (p40 or p70) in the serum after vaccina tion with MMLADV (Fig. 5 A) or from BMDC stimulated with MMLADV in vitro (Fig. 5 B) , although IL12 p40 was detected in LN DC immediately ex vivo after immunization compared with control mice (Fig. 5 C) . However, there was no increase in IL12 production in response to MMLADV when IL10 was absent or inhibited (Fig. 5, AC) . Thus, innate IL10 produc tion has no influence on the magnitude, quality, or IL10-producing capacity of Th1 cells after highdose MMLADV immunization.
The other vaccine formulation that we have previ ously studied for generating protective multifunctional Th1 responses against L. major in mice is MML protein with CpG (MML + CpG). With this vaccine approach, CpG promotes Th1 immunity through production of IL12 from DCs (Chu et al., 1997; Roman et al., 1997; Fig. 5) . CpG also induces production of IL10 from innate immune cells (Boonstra et al., 2006; Samarasinghe et al., 2006; Fig. 5, A and B) . Impor tantly, inhibition of such innate IL10, through use of either IL10 / mice or IL10R treatment, increases the amount of CpGinduced IL12 p40 and IL12 p70 in the serum (Fig. 5 A) from BMDC stimulated in vitro (Fig. 5 B) and from LN DC ex vivo (Fig. 5 C) .
The magnitude and quality of the Th1 response after MML + CpG immunization is enhanced in the absence of IL-10 Fig. 5 shows that IL12 production by APCs can be signifi cantly increased by the inhibition of IL10 during immuni zation with CpG; thus, we hypothesized that IL10 may the efficiency of the MML + CpG vaccine regimen, mice were immunized once with MML + CpG in the presence (WT) or absence (IL10 / ) of IL10 or IL10 signaling (IL10R treatment). As shown in Fig. 6 A, there was a dramatic increase in the total magnitude of IFN-, IL2-, and TNFproducing CD4 + T cells 23 d after a single vaccination with MML + CpG in the absence of IL10 or IL10 signaling compared with WT mice. It is of note that IL10-producing CD4 + T cells were not detected after a single vaccination of limit Th1 differentiation when using a CpG vaccine regi men. In this regard, three immunizations with MML + CpG are required to elicit a high frequency of multifunctional Th1 cells and protection after vaccination (Darrah et al., 2007) . To assess whether manipulating IL10 could enhance was blocked using IL10R rather than using IL10 / mice (Fig. 6, A-D) , suggesting that compensatory mechanisms might exist in IL10 / mice.
The effect of IL-10 on enhancing the Th1 response to MML + CpG is IL-12 dependent
The dramatic change in magnitude and quality of the Th1 response after a single vaccination of MML + CpG in the ab sence of IL10 or IL10 signaling (Fig. 6) was likely driven by an increase in IL12 because CpGinduced IL12 was signifi cantly enhanced in vitro and in vivo in the absence of IL10 (Fig. 5) . Accordingly, when IL10 / mice were treated with a neutralizing antibody to IL12 (IL12) at the time of a single immunization with MML + CpG, the median fre quencies of IFN, IL2, and TNF compared with control antibody (Ctrl Ab)-treated IL10 / mice were decreased by 4.3, 1.7, and 1.9fold, respectively (Fig. 7 A) . Notably, the frequency of IFN + IL2 + TNF + multifunctional cells that produce high levels of IFN and correlate with protec tion (Darrah et al., 2007) , as well as IFN + IL2  TNF + T cells, was significantly decreased (4.1 and 6.6fold, respec tively) by IL12 treatment (Fig. 7 B) . Furthermore, the quality of the Th1 response in IL12-treated MML + CpG-immunized IL10 / mice (Fig. 7 C) appeared less dif ferentiated than Ctrl Ab-treated IL10 / mice, as the pro portion of cells producing only TNF or TNF and IL2 (IFN negative) was greater (69 vs. 32%). This less differen tiated quality resembled the response in untreated WT mice receiving the same vaccine (Fig. 6 D, top) . These data suggest that the neutralization of IL12 effectively limited the extent of vaccineinduced Th1 differentiation in the absence of IL10. Furthermore, immunization of IL12 p40 / mice confirmed the role of IL12 in driving the magnitude and differentiation of the Th1 response after MML + CpG vacci nation (Fig. S5) . Lastly, IL12 treatment of IL10 / mice at the time of vaccination resulted not only in lower frequen cies of IFN-producing Th1 populations but in IFN + IL2 + TNF + and IFN + IL2  TNF + cells that secreted less IFN on a per cell basis (note log scale; Fig. 7 D) and less antigenspecific IFN production overall (Fig. 7 E) com pared with Ctrl Ab-treated vaccinated IL10 / mice.
The effect of IL-10 on enhancing the Th1 response to MML + CpG is indirect
The previous data suggest that CpGinduced IL10 limits the Th1 response to MML + CpG by restricting IL12 production by APCs; however, a direct role for IL10 on CD4 + T cells could not be excluded. To assess the in vivo mechanism for how vaccineinduced IL10 influences Th1 immunity, BM chimera mice were generated by reconstituting irradiated Rag1 / mice with equal numbers of CD45disparate WT and IL10R / BM cells. Such mice provided a model to assess whether WT (IL10R +/+ ) and IL10R / Th1 cells generated within the same animal and under identical innate conditions would differ in the magnitude or quality after MML + CpG vaccination. Rag1 / control mice reconstituted with only MML + CpG. In addition, there was a significant increase in the IFN, IL2, and TNF MFI (note log scale; Fig. 6 B) , sug gesting an underlying difference in the quality of the response. Indeed, of the four cytokineproducing populations that were significantly increased in the absence of IL10 or IL10 signal ing, the most striking increase was in the multifunctional (IFN + IL2 + TNF + ) CD4 + T cells (Fig. 6 C) that produce significantly more IFN (and therefore have a higher IFN MFI) than double or single IFN-producing CD4 + T cells and correlate with protection against L. major (Darrah et al., 2007) . Thus, whereas WT animals generated low frequencies of predominantly TNF or TNF and IL2-producing cells, animals vaccinated once with MML + CpG in the absence or blocking of IL10 had a higher response with increased differ entiation toward IFN-producing cells (Fig. 6 D) . It is of note that we consistently noted a greater effect when IL10 In this paper, we have demonstrated that IL10R treatment at the time of immunization dramatically enhances the magnitude and quality of the Th1 re sponse to a single vaccination with MML + CpG. Thus, we sought to determine how Th1 re sponses elicited by a single immunization of MML + CpG in the presence of IL10R compared with those elicited by three consecutive vaccinations in WT mice. When Th1 responses were analyzed 21 d after one (1×), two (2×), or three (3×) MML + CpG vaccinations with Ctrl Ab in WT mice, there was a clear hierarchy in the frequency (Fig. 9 A) and proportion (Fig. 9 B) of IFN + IL2 + TNF + and IFN + IL2  TNF + Th1 cells that correlated with the number of vaccinations. These data indicate that repetitive vaccination drives Th1 differentiation and are consistent with a linear differentiation model (Seder et al., 2008) . Notably, the response elicited by a single vaccination of MML + CpG in WT mice treated with IL10R (1× + IL10R) appeared remarkably similar to the response observed in mice vacci nated 3× + Ctrl Ab, with respect to the frequency of multi functional cells (Fig. 9 A) as well as the overall proportion of IFN-producing cells (Fig. 9 B, black arc) . To further as sess whether these populations of CD4 + T cells were func tionally equivalent, we compared their proliferative capacity, avidity for peptide, and ability to confer protection. Com pared with 3×vaccinated mice, CD4 + T cells from 1× + IL10R-vaccinated mice proliferated to the same ex tent (Fig. S6 A) and, in preliminary studies, had comparable functional avidity (EC 50 : 1× + IL10R, 70 ng/ml; 3×, 80 ng/ml; Fig. S6 B) . The only evidence for a functional differ ence between mice receiving these vaccine regimens was in the trafficking of antigenspecific cells into the site of infection after L. major challenge. At 10 d after challenge, a significantly WT cells had low but detectable frequencies of IFN-, IL2-, or TNFproducing CD4 + T cells after only a single vaccina tion of MML + CpG (Fig. 8 A) . In contrast, much higher Th1 responses were measured in Rag1 / control mice reconsti tuted with only IL10R / BM, in which all cells (including T cells and APCs) are refractory to IL10 (Fig. 8 B) . In mixed chimeric mice immunized with MML + CpG (Fig. 8, C-E) , paired comparisons of WT and IL10R / cytokine frequen cies within the same mouse failed to demonstrate significant differences (Fig. 8 C) in two separate experiments (note sym bols). Despite variation in the magnitude of cytokine produc tion between mice, the ratio of IL10R / to WT cytokine frequencies within the same mouse (Fig. 8 D) was consistent and was not significantly different than 1.0 (equal response ratio). Furthermore, there were no significant differences (by paired analysis) in the frequency of multifunctional cells be tween WT and IL10R / Th1 cells (Fig. 8 E) or in the ca pacity of these populations to produce IFN (Fig. 8 F) . These data show that the restrictive effect of IL10 on Th1 generation and differentiation after MML + CpG vaccination is not di rectly on T cells but on APCs to limit IL12 production.
A single immunization with MML + CpG in the absence of IL-10 confers protection
We previously reported that three immunizations with MML + CpG elicits a high frequency of multifunctional IFN + IL2 + TNF + Th1 cells and confers protection (Darrah et al., 2007) . determined by ear lesion progression over time (Fig. 9 C) or parasite burdens (Fig. 9 D) . Thus, blocking the effects of IL10 only at the time of immunization converted the low magni tude and less differentiated quality elicited by a single MML + CpG vaccination into a robust vaccine that elicits a high fre quency of multifunctional Th1 cells and protects as well as three vaccinations in WT mice.
DISCUSSION
In this paper, we extend our previous findings that a Th1 re sponse of a particular quality is necessary to mediate protection against an intracellular infection, using two different vaccine modalities. Our study focused on the influence of vaccine induced IL10 from CD4 + T cells or APCs on the magnitude, quality, and protective capacity of the Th1 response. The data show a dosedependent increase in IL10 production by CD4 + T cells after immunization with MMLADV; however, such CD4 + T cellderived adaptive IL10 did not impact Th1 im munity or protection. In contrast, inhibition of innate IL10 produced by APCs at the time of immunization with MML + CpG significantly enhanced the magnitude of the response and the extent of Th1 differentiation and, importantly, increased protection. Together, these data demonstrate how IL10 can be manipulated to achieve favorable Th1 quality and protec tion, depending on the vaccine platform. The mechanisms un derlying these findings should inform vaccine design against infections requiring Th1 responses for protection.
In choosing specific vaccine platforms, recombinant ADV vectors are of broad interest based on their potential use as vaccines to prevent HIV, malaria, and tuberculosis infection. Among the various ADV serotypes, serotype 5 is the most po tent inducer of T cell responses (Thorner et al., 2006) . In this paper, we show that lowdose MMLADV elicits a favorable Th1 quality and very few IL10-producing CD4 + T cells, and it protects mice from L. major challenge. In contrast, highdose MMLADV elicits a poor quality Th1 response and a high frequency of IL10-producing CD4 + T cells, and it does not protect. Further characterization of the Th1 response to high dose MMLADV at the singlecell level revealed that a major ity of the IL10 produced was from CD4 + CD25  Foxp3  T cells that also produced IFN with or without TNF, which is indicative of a Th1 lineage. Several recent studies have dem onstrated dramatic effects of CD4 + T cell-derived IL10 in vivo in the context of ongoing infection. In this regard, IL10 production by CD4 + IFN + Th1 cells limits an excessive pro inflammatory response during the course of T. gondii (Jankovic et al., 2007) and Flu infections (Sun et al., 2009) . Furthermore, in the setting of chronic L. major infection, production of IL10 by CD4 + IFN + Th1 cells limits parasite killing and protec tion (Anderson et al., 2007) . With regard to vaccines, IL10R treatment increased vaccineelicited protection in the BALB/c model of L. major infection (Stober et al., 2005) . In the latter study, it was speculated that blocking IL10 derived from CD4 + CD25 + Tr1like cells during the course of infection en hanced protection (Stober et al., 2005) . Given the findings in the L. major model, we hypothesized that IL10-producing larger frequency of Th1 cells had migrated into the ears of mice vaccinated 3× with MML + CpG compared with mice vaccinated 1× + IL10R (Fig. S7) . However, despite the difference in frequency of antigenspecific Th1 cells in the ear shortly after infection, mice vaccinated 1× + IL10R were protected as well as those vaccinated 3× + Ctrl Ab as The data from the MML + CpG vaccinations provide a mechanism for why multiple immunizations are required to elicit a frequency of multifunctional Th1 cells sufficient for protection using a protein vaccine with a TLR ligand that in duces both IL10 and IL12. IL10 can protect the host by downregulating IL12-driven proinflammatory Th1 re sponses during infection with T. gondii or influenza or expo sure to LPS (Gérard et al., 1993; Howard et al., 1993; Jankovic et al., 2007; Sun et al., 2009 ). However, the same negative feedback limits Th1 generation and differentiation when adapt ing the constituents of such pathogens as vaccine adjuvants. The finding that limiting IL10 can dramatically enhance Th1 responses generated by protein and TLR ligandbased vaccine formulations has implications for improving vaccine design in humans. Most proteinbased vaccines must be given several times over a prolonged period of time to induce a protective response. If transient inhibition of IL10 improves the effi ciency of vaccination so that fewer immunizations are required, it might increase compliance and save cost in resourcepoor areas. In this regard, inclusion of p38 MAPK inhibitor in creased the protection of a lowdose CpGbased pertussis vac cine regimen through inhibition of T reg cell-derived IL10, although a specific effect on the Th1 response was not demon strated (Jarnicki et al., 2008) . This paper shows the effects of IL10 by CD4 + T cells and APCs in the context of protection using different vaccine regi mens. Indeed, we demonstrate that three vaccines (lowdose MMLADV, 3× MML + CpG, and 1× MML + CpG +  IL10R) elicited Th1 responses of comparable frequency, quality, and level of protection. Importantly, the mechanisms by which these vaccines elicit such responses appear distinct visàvis the role of innate immunity, antigen dose, persistence, and repetitive immunization. We have incorporated these variables in our model of Th1 differentiation (Fig. S8) . In con clusion, balancing the extent of Th1 differentiation to achieve protective and durable Th1 immunity remains a hurdle for developing vaccines for infections such as leishmaniasis and tuberculosis. This study provides insight into how vaccines can be manipulated to achieve protective immunity.
MATERIALS AND METHODS
Mice. Female C57BL/6 (B6), B6.IL10 / , B6.IL10R / , B6.IL12 p40 / , B6.CD45.1, and B6.RAG1 / were obtained from The Jackson Laboratory. BM chimeras were generated by injecting 2.5 × 10 6 BM cells from B6.IL10R / (CD45.2) and WT B6.CD45.1 mice into irradiated (650 rad) B6.Rag1 / mice. All mice were maintained in animal care facili ties at the National Institutes of Health under pathogenfree conditions and all experiments were approved by the Vaccine Research Center animal care and use committee.
Immunizations and in vivo mAb treatment. MML (also known as Leish111f) is a recombinant polyprotein derived from Leishmania species, shown to be protective in vivo, and comprising three proteins: TSA (also known as MAPS), LmSTI1 (also known as M15), and LeIF (Skeiky et al., 2002 CD4 + T cells elicited by highdose MMLADV immunization limited control of infection. Surprisingly, in the absence of IL10 or IL10 signaling at the time of vaccination or through out the infection, the magnitude or the quality of the Th1 response after highdose MMLADV immunization was not enhanced nor was the protection improved. As we were unable to demonstrate production of other inhibitory cytokines (IL4, IL13, and TGF) from CD4 + T cells after highdose MMLADV immunization (unpublished data), these data un derscore that the quality of the Th1 response is a necessary de terminant of protection against L. major infection. Because a single immunization with MMLADV can confer protection when given at a lower dose, it is likely that the quality of the re sponse can be negatively impacted by the vector providing more antigen, altered innate immunity, or both. Studies to ana lyze the effect of each of these variables on the quality of the Th1 response are underway.
The other vaccine formulation analyzed in this study was MML + CpG. Protein vaccines formulated with TLR ligands, such as monophosphoryl lipid A, are currently being tested in humans for prevention of leishmaniasis, tuberculosis, and ma laria (Coler and Reed, 2005; Skeiky and Sadoff, 2006; Coler et al., 2009) . They offer an advantage over certain viral vaccines in that they potently elicit both antibody and Th1 responses and can be used repetitively. Paradoxically, some TLR ligands, such as CpG or LPS, can prime Th1 responses through induc tion of IL12 but also elicit the inhibitory cytokine IL10 (Chu et al., 1997; Roman et al., 1997; Boonstra et al., 2006; Samarasinghe et al., 2006) . Thus, we hypothesized that Th1 responses would be significantly altered by inhibiting IL10 after vaccination with MML + CpG. Indeed, IL10R treat ment has been shown to enhance the Th1 recall response to soluble ovalbumin protein when primed in the presence of the LPS (Castro et al., 2000) . In this paper, we extended these findings by defining the role that IL10 has in the magnitude and quality of the Th1 response at the singlecell level in a model that allowed us to assess vaccineelicited protection. CpG elicited high amounts of innate IL12 (p40 and p70) and IL10 in the serum after injection or from BMDCs stimulated in vitro; moreover, IL12 levels were enhanced in IL10 / mice. In addition, the amount of IL12 expressed ex vivo by LN DCs isolated after CpG immunization was higher when IL10 signaling was inhibited. Such perturbations in IL10 production also had a striking effect on vaccineelicited Th1 responses. Vaccination of IL10 / or IL10R-treated mice with a single injection of MML + CpG dramatically increased the magnitude of the Th1 response, altered the Th1 quality, and enhanced protection compared with a single vaccination of WT mice in an IL12-dependent manner. Last, MML + CpG vaccination of BM chimera mice revealed no difference in a WT or IL10R / Th1 response generated under identi cal innate conditions within the same mouse, ruling out a di rect role of IL10 on CD4 + T cells. Thus, innate IL10 inhibits IL12 production from DCs and limits the extent of Th1 dif ferentiation in response to a transient amount of protein antigen when given with CpG.
Proliferation assay. Splenocytes harvested from mice 17 d after vaccination were labeled with 0.25 µM CFSE (Invitrogen) at a concentration of 1.0 × 10 6 cells/ml in PBS for 7 min at 37°C. Cells were washed and cultured in dupli cate at a concentration of 3.0 × 10 6 cells/ml/tube in the presence of 5 µg/ml MML for 5-6 d, protected from light. For the final 7 h, 1 µg/ml (each) MML peptides and 10 µg/ml BFA were added, followed by ICS as described in Multi parameter flow cytometry. A mean of 10 5 live T cells were analyzed per sample.
Statistics. All cytokine frequencies are reported after background subtraction of the frequency of the identically gated population of cells from the same sample stimulated without antigen. Bars in figures show the median of indi vidual mice (dots in figures). Total spleen cell counts and total numbers of viable CD4 + T cells were not significantly different between vaccine groups within the same experiment. All comparisons (bar and pie charts) of cytokine production between vaccine groups were done in SPICE v4.2.3 using a two tailed Student's t test assuming unequal variances or Wilcoxinrank test (for n ≥ 4 mice). For BM chimeras, a paired analysis (t test and Wilcoxin) was used to compare responses of BM subsets within the same mouse. For challenge data, area under the curve or lesion sizes at individual time points were com pared by Student's t test using SigmaPlot (version 8; Systat Software Inc.) or JMP v5.1 (SAS Institute Inc.). Avidity was determined by a nonlinear least squares fit of a standard MichaelisMenten binding curve using JMP (version 5.1). Significance was determined by comparing the EC 50 (effective concen tration that elicits half of the maximum response) for titrations from each in dividual mouse. For all comparisons, pvalues <0.05 are noted.
Online supplemental material. Fig. S1 shows that highdose MMLADV does not induce T reg cells and elicits IL10 from CD4 + CD25  Foxp3  T cells. Fig. S2 shows that s.c. immunization with highdose MMLADV vaccination elicits IL10-producing CD4 + T cells. Fig. S3 shows that block ing IL10 signaling at the time of s.c. immunization with highdose MML ADV does not influence the generation of Th1 or IL10-producing CD4 + T cells. Fig. S4 demonstrates that IL10 does not impact the magnitude, quality, or protective capacity of the Th1 response after s.c. immunization with highdose MMLADV. Fig. S5 confirms the role of IL12 p40 in driv ing the magnitude and differentiation of the Th1 response after MML + CpG vaccination. Fig. S6 demonstrates that antigenspecific CD4 + T cells generated after vaccination with 3× MML + CpG or 1× MML + CpG + IL10R display comparable proliferation and functional avidity in vitro. 
